68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer
PurposeTo synthesize the dimer of GX1 and identify whether its affinity and targeting are better than those of GX1. To prepare 68Ga-DOTA-KEK-(GX1)2 and to apply it to PET and Cerenkov imaging of gastric cancer.Methods68Ga-DOTA-KEK-(GX1)2 was prepared, and the labeling yield and stability were determ...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.750376/full |
id |
doaj-a32869c7af17484f877da7519ef07527 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jipeng Yin Jipeng Yin Bo Xin Mingru Zhang Xiaoli Hui Na Chai Hao Hu Bing Xu Jing Wang Yongzhan Nie Guangqing Zhou Guanliang Wang Hongbing Lu Liping Yao Liusheng Chen Kaichun Wu |
spellingShingle |
Jipeng Yin Jipeng Yin Bo Xin Mingru Zhang Xiaoli Hui Na Chai Hao Hu Bing Xu Jing Wang Yongzhan Nie Guangqing Zhou Guanliang Wang Hongbing Lu Liping Yao Liusheng Chen Kaichun Wu 68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer Frontiers in Oncology gastric cancer GX1 dimer PET imaging Cerenkov imaging TGM2 |
author_facet |
Jipeng Yin Jipeng Yin Bo Xin Mingru Zhang Xiaoli Hui Na Chai Hao Hu Bing Xu Jing Wang Yongzhan Nie Guangqing Zhou Guanliang Wang Hongbing Lu Liping Yao Liusheng Chen Kaichun Wu |
author_sort |
Jipeng Yin |
title |
68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer |
title_short |
68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer |
title_full |
68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer |
title_fullStr |
68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer |
title_full_unstemmed |
68Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer |
title_sort |
68ga-labeled gx1 dimer: a novel probe for pet/cerenkov imaging targeting gastric cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
PurposeTo synthesize the dimer of GX1 and identify whether its affinity and targeting are better than those of GX1. To prepare 68Ga-DOTA-KEK-(GX1)2 and to apply it to PET and Cerenkov imaging of gastric cancer.Methods68Ga-DOTA-KEK-(GX1)2 was prepared, and the labeling yield and stability were determined. Its specificity and affinity were verified using an in vitro cell binding assay and competitive inhibition test, cell immunofluorescence, and cell uptake and efflux study. Its tumor-targeting ability was determined by nano PET/CT and Cerenkov imaging, standardized uptake value (SUV), signal-to-background ratio (SBR) quantification, and a biodistribution study in tumor-bearing nude mice.Results68Ga-DOTA-KEK-(GX1)2 was successfully prepared, and the labeling yield was more than 97%. It existed stably for 90 min in serum. The binding of 68Ga-DOTA-KEK-(GX1)2 to cocultured HUVECs (Co-HUVECs) was higher than that to human umbilical vein endothelial cells (HUVECs), BGC823 cells, and GES cells. It was also higher than that of 68Ga-DOTA-GX1, indicating that the dimer did improve the specificity and affinity of GX1. The binding of KEK-(GX1)2 to Co-HUVECs was significantly higher than that of GX1. Additionally, the uptake of 68Ga-DOTA-KEK-(GX1)2 by Co-HUVECs was higher than that of 68Ga-DOTA-GX1 and reached a maximum at 60 min. Nano PET/CT and Cerenkov imaging showed that the tumor imaging of the nude mice injected with 68Ga-DOTA-KEK-(GX1)2 was clear, and the SUV and SBR value of the tumor sites were significantly higher than those of the nude mice injected with 68Ga-DOTA-GX1, indicating that the probe had better targeting in vivo. Finally, the biodistribution showed quantitatively that when organs such as the kidney and liver metabolized rapidly, the radioactivity of the tumor site of the nude mice injected with 68Ga-DOTA-KEK-(GX1)2 decreased relatively slowly. At the same time, the percentage of injected dose per gram (%ID/g) of the tumor site was higher than that of other normal organs except the liver and kidney at 60 min, which indicated that the tumor had good absorption of the probe.ConclusionGX1 was modified successfully, and the in vivo and in vitro properties of the GX1 dimer were significantly better than those of GX1. The imaging probe, 68Ga-DOTA-KEK-(GX1)2, was successfully prepared, which provides a candidate probe for PET and Cerenkov diagnosis of gastric cancer. |
topic |
gastric cancer GX1 dimer PET imaging Cerenkov imaging TGM2 |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.750376/full |
work_keys_str_mv |
AT jipengyin 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT jipengyin 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT boxin 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT mingruzhang 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT xiaolihui 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT nachai 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT haohu 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT bingxu 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT jingwang 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT yongzhannie 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT guangqingzhou 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT guanliangwang 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT hongbinglu 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT lipingyao 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT liushengchen 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer AT kaichunwu 68galabeledgx1dimeranovelprobeforpetcerenkovimagingtargetinggastriccancer |
_version_ |
1716863812724850688 |
spelling |
doaj-a32869c7af17484f877da7519ef075272021-09-30T07:49:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.75037675037668Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric CancerJipeng Yin0Jipeng Yin1Bo Xin2Mingru Zhang3Xiaoli Hui4Na Chai5Hao Hu6Bing Xu7Jing Wang8Yongzhan Nie9Guangqing Zhou10Guanliang Wang11Hongbing Lu12Liping Yao13Liusheng Chen14Kaichun Wu15School of Biomedical Engineering, Fourth Military Medical University, Xi’an, ChinaClinical Medical Research Center, The 75th Group Army Hospital of Chinese People’s Liberation Army (PLA), Dali, ChinaDepartment of Oncology, No. 960 Hospital of PLA, Taian, ChinaDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaFirst Affiliated Hospital, Xi’an Jiaotong University, Xi’an, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, ChinaDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, ChinaClinical Medical Research Center, The 75th Group Army Hospital of Chinese People’s Liberation Army (PLA), Dali, ChinaClinical Medical Research Center, The 75th Group Army Hospital of Chinese People’s Liberation Army (PLA), Dali, ChinaSchool of Biomedical Engineering, Fourth Military Medical University, Xi’an, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, ChinaClinical Medical Research Center, The 75th Group Army Hospital of Chinese People’s Liberation Army (PLA), Dali, ChinaState Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, ChinaPurposeTo synthesize the dimer of GX1 and identify whether its affinity and targeting are better than those of GX1. To prepare 68Ga-DOTA-KEK-(GX1)2 and to apply it to PET and Cerenkov imaging of gastric cancer.Methods68Ga-DOTA-KEK-(GX1)2 was prepared, and the labeling yield and stability were determined. Its specificity and affinity were verified using an in vitro cell binding assay and competitive inhibition test, cell immunofluorescence, and cell uptake and efflux study. Its tumor-targeting ability was determined by nano PET/CT and Cerenkov imaging, standardized uptake value (SUV), signal-to-background ratio (SBR) quantification, and a biodistribution study in tumor-bearing nude mice.Results68Ga-DOTA-KEK-(GX1)2 was successfully prepared, and the labeling yield was more than 97%. It existed stably for 90 min in serum. The binding of 68Ga-DOTA-KEK-(GX1)2 to cocultured HUVECs (Co-HUVECs) was higher than that to human umbilical vein endothelial cells (HUVECs), BGC823 cells, and GES cells. It was also higher than that of 68Ga-DOTA-GX1, indicating that the dimer did improve the specificity and affinity of GX1. The binding of KEK-(GX1)2 to Co-HUVECs was significantly higher than that of GX1. Additionally, the uptake of 68Ga-DOTA-KEK-(GX1)2 by Co-HUVECs was higher than that of 68Ga-DOTA-GX1 and reached a maximum at 60 min. Nano PET/CT and Cerenkov imaging showed that the tumor imaging of the nude mice injected with 68Ga-DOTA-KEK-(GX1)2 was clear, and the SUV and SBR value of the tumor sites were significantly higher than those of the nude mice injected with 68Ga-DOTA-GX1, indicating that the probe had better targeting in vivo. Finally, the biodistribution showed quantitatively that when organs such as the kidney and liver metabolized rapidly, the radioactivity of the tumor site of the nude mice injected with 68Ga-DOTA-KEK-(GX1)2 decreased relatively slowly. At the same time, the percentage of injected dose per gram (%ID/g) of the tumor site was higher than that of other normal organs except the liver and kidney at 60 min, which indicated that the tumor had good absorption of the probe.ConclusionGX1 was modified successfully, and the in vivo and in vitro properties of the GX1 dimer were significantly better than those of GX1. The imaging probe, 68Ga-DOTA-KEK-(GX1)2, was successfully prepared, which provides a candidate probe for PET and Cerenkov diagnosis of gastric cancer.https://www.frontiersin.org/articles/10.3389/fonc.2021.750376/fullgastric cancerGX1 dimerPET imagingCerenkov imagingTGM2 |